However, that number is skewed due to Pfizer's year-end results. In the last three months of 2024, the company incurred ...

Architect Levitt Bernstein, in collaboration with low energy specialist Etude, has developed a three-part document package for Greater Manchester Combined Authority, to help applicants comply with the ...

O’Reilly Auto Parts will become the title sponsor for NASCAR’s second-tier national series when the Xfinity Series is renamed ...

Key Takeaways With economic data sending mixed signals and stock valuations at historic highs, Wall Street could be headed for a rough patch, according to analysts at Evercore ISI. Evercore analysts ...

The Company has launched a multi-layered exploration program – including a 395-sample soil geochemistry survey, a high-resolution ground magnetic survey scheduled for September, and newly processed ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Pfizer is advancing research and building a comprehensive "toolbox" for Vietnamese patients, combining innovative vaccines, ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...